TICKERNERD
Menu
AARDAARDHealthcare · Biotechnology

AARD Stock Forecast: Aardvark Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.71
−5.04% on the day

The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. hold a median 12-month price target of $6 — +27.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$110.3M
Ticker Nerd rank
19 / 100
Median analyst target
$6.00
Analysts covering
12
Revenue$0.0
Operating income−$15.1M
Net income−$14.4M
Free cash flow−$17.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.6%
1M
−11.6%
YTD
−64.1%
1Y
−72.5%
From 52W high
−72.5%
From 52W low
+35.3%
$3
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AARD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aardvark Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
75
Revisions
61
Accruals
38
Issuance
32
Value
32
Quality
30
Growth
17
Momentum
17
Volatility
7

Size (75): Smaller than most of the companies we track.

Volatility (7): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AARD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AARD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26AARDHigh $28.00Median $6.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
6 Buy4 Hold2 Sell
Low $3.00Median $6.00High $28.00

The green dot is the last close — the median target sits +27.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2026RBC CapitalReiteratesSector Perform$6.00
20 July 2026HC Wainwright & Co.ReiteratesNeutral$6.00
20 July 2026HC Wainwright & Co.ReiteratesNeutral—
15 May 2026B. Riley SecuritiesMaintainsBuy$8.00 → $7.00
15 May 2026B. Riley SecuritiesMaintainsBuy—
15 May 2026BTIGDowngradeNeutral—
15 May 2026BTIGDowngradeNeutral—
15 May 2026Morgan StanleyDowngradeUnderweight$7.00 → $3.00
15 May 2026Morgan StanleyDowngradeUnderweight—
24 Mar 2026BTIGReiteratesBuy—
2 Mar 2026BTIGMaintainsBuy—
2 Mar 2026HC Wainwright & Co.DowngradeNeutral—
2 Mar 2026Morgan StanleyDowngradeEqual-Weight—
2 Mar 2026OppenheimerMaintainsOutperform—
2 Mar 2026RBC CapitalDowngradeSector Perform—
2 Mar 2026StifelDowngradeHold—
10 Feb 2026BTIGReiteratesBuy—
9 Feb 2026HC Wainwright & Co.ReiteratesBuy—
23 Dec 2025OppenheimerInitiatesOutperform—
12 Dec 2025William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AARD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AARD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Aardvark Therapeutics, Inc. returned −72.5% against +16.2% for the S&P 500, dividends included.

AARD vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26AARDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AARD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
1
Fundamentals

Aardvark Therapeutics, Inc. (AARD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
−0.5×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−66.0%

Higher than 18% of US stocks

Return on assets
−40.4%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aardvark Therapeutics, Inc. (AARD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aardvark Therapeutics, Inc. has a market value of $110.3M and an enterprise value of $37.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$69.9M.

  • Diluted earnings per share, trailing twelve months: $−3.21.

  • Free cash flow in the twelve months to 30 June 2026: −$69.4M.

  • Shares outstanding: 21.9M.

  • Trailing P/E: −1.7×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aardvark Therapeutics, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

AARD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AARDAardvark Therapeutics, Inc.$110.3M
19
IMUXImmunic, Inc.$103.0M
29
BDTXBlack Diamond Therapeutics, Inc.$103.7M
56
PLYXPolaryx Therapeutics, Inc.$99.7M
16
PYPDPolyPid Ltd.$99.5M
56
CRBPCorbus Pharmaceuticals Holdings, Inc.$97.6M
19
ANIXAnixa Biosciences, Inc.$97.6M
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aardvark Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AARD news & analysis

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 8 Oct 2026negative

Schall, Brown & Schwartz LLP announced a class action lawsuit against Aardvark Therapeutics alleging violations of federal securities laws. The firm invited shareholders who purchased AARD shares during the stated class period to contact it about possible lead plaintiff appointments.

Why it matters — The lawsuit and lead-plaintiff outreach are developments relevant to investors following AARD’s securities litigation.

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

GlobeNewsWire · 8 Oct 2026positive

Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, to its Board of Directors. Zhang brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions, including roles at Abivax, Alumis, MyoKardia and Genentech/Roche.

Why it matters — AARD watchers may note the addition of an experienced clinical development leader to the company's board.

Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 6 Oct 2026negative

Glancy Prongay Wolke & Rotter LLP reminded investors that October 13, 2026 is the deadline to file a lead plaintiff motion in a securities class action involving Aardvark Therapeutics investors. The action covers securities purchased or acquired from February 10, 2025, through May 14, 2026.

Why it matters — AARD watchers may note the class action and its upcoming lead plaintiff motion deadline concerning investors in the company.

FAQ

Frequently asked questions about AARD stock

What is the AARD stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AARD stock a buy right now?

Of the 12 analysts covering Aardvark Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Aardvark Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AARD?

As at 8 Oct 2026, Aardvark Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).

Will AARD stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +27.4% from the last close, and Ticker Nerd's factor model ranks Aardvark Therapeutics, Inc. 19 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AARD stock forecast for 2030?

No analyst covering Aardvark Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $28 over the next 12 months.

How has AARD stock performed over the past year?

Aardvark Therapeutics, Inc. returned -72.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aardvark Therapeutics, Inc. do?

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases and hunger-related conditions.

What is the latest news on AARD?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law". Schall, Brown & Schwartz LLP announced a class action lawsuit against Aardvark Therapeutics alleging violations of federal securities laws. The firm invited shareholders who purchased AARD shares during the stated class period to contact it about possible lead plaintiff appointments.

Company

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for metabolic diseases and hunger-related conditions. The company’s current work centers on oral, gut-restricted drug candidates designed to activate bitter taste receptors in the digestive tract and influence satiety signaling through the gut-brain axis. Its lead program, ARD-101, is being developed for hyperphagia associated with Prader-Willi syndrome and other hunger-associated rare diseases, while additional programs explore applications in obesity and related metabolic disorders. Aardvark Therapeutics operates in the biopharmaceutical and health technology sectors, with a research-driven model built around advancing investigational therapies through clinical development for conditions with limited treatment options. Founded in 2017 and headquartered in San Diego, California, the company focuses on translating its proprietary science into targeted treatments for patients affected by metabolic and inflammatory disease pathways.

CEO Dr. Tien-Li Lee M.D. · 28 employees · United States · https://aardvarktherapeutics.com